The Science of Monoclonal Antibodies and the Emergence of VYEPTI® (eptinezumab-jjmr) for the Preventive Treatment of Migraine


What is Migraine?

Migraine Pathophysiology and the Role of CGRP

Therapeutic Monoclonal Antibodies: A Review

Eptinezumab-jjmr Antibody Science: Pharmacokinetics and MOA

VYEPTI® (eptinezumab-jjmr) in Migraine Prevention: Clinical and Safety Data

VYEPTI® (eptinezumab-jjmr) in Migraine Prevention: Safety and Dosing

Patient Considerations


VYEPTI is indicated for the preventive treatment of migraine in adults.

Important Safety Information

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.


Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.


The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

For more information, please see the Prescribing Information and Patient Information.

Meet the Speakers

Jessica Ailani, MD, FAHS, FAAN

Jessica Ailani, MD, FAHS, FAAN

Professor of Clinical Neurology
Director, Georgetown Headache Center
MedStar Georgetown University Hospital
Washington, DC

Jessica Ailani, MD, FAHS, FAAN is a Professor of Clinical Neurology and Director of the MedStar Georgetown Headache Center at MedStar Georgetown University Hospital in Washington, DC. She received her medical degree from the Stony Brook University School of Medicine in New York, followed by an internship at Winthrop University Hospital in Mineola, New York. Dr. Ailani subsequently completed a residency and Chief Residency in Neurology at NYU Langone Medical Center in New York, New York, followed by a fellowship in Headache Medicine at Thomas Jefferson University in Philadelphia, Pennsylvania. She is board-certified in Neurology with subspecialty certification in Headache Medicine.

Dr. Ailani is a fellow of the American Headache Society (AHS) and of the American Academy of Neurology. She holds a position on the board of the American Headache Society as a member at large. For AHS, Dr. Ailani is a co-chair of the Practice Management Committee and is on the Scientific and Scottsdale Program Planning Committees. Dr. Ailani is Section Editor of Unusual Headache Syndromes for Current Pain and Headache Reports and a reviewer for several professional journals. Dr. Ailani has presented nationally on topics surrounding headache medicine.

View More
R Lor Randall, M.D., FACS head shot

Andrew Charles, MD

Professor of Neurology
Meyer and Renee Luskin Chair in Migraine and Headache Studies
Director, Goldberg Migraine Program
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA

Andrew Charles, MD is a Professor of Neurology at the UCLA School of Medicine, where he directs the Goldberg Migraine Program and holds the Meyer and Renee Luskin Chair in Migraine and Headache Studies. He received his undergraduate degree from the University of California, Berkeley, his MD from the UCLA School of Medicine, did his internship at Harbor-UCLA medical center, and neurology residency training at UCLA. He has been on the faculty of the UCLA Department of Neurology since 1992.

His laboratory focuses on cellular and pharmacological mechanisms of migraine and pain, with a particular interest in the development of novel therapies. He is an associate editor of the journal Cephalalgia, and he has served on the Board of Trustees of the International Headache Society. He is currently the President Elect of the American Headache Society. He has published widely on basic and clinical aspects of migraine and pain, and lectures nationally and internationally on these topics.

View More

Speaker Disclosure

This event is sponsored by Lundbeck and is not approved for Continuing Medical Education.
We are presenting the information on behalf of Lundbeck and will be compensated by Lundbeck for presenting.
We are required to present all information in compliance with the FDA requirements applicable to Lundbeck.

Program Objectives


Review migraine pathophysiology, the role of CGRP, and the rationale for CGRP as a therapeutic target in migraine prevention


Evaluate the pharmacokinetics and potential mechanism of action of eptinezumab-jjmr


Provide perspectives on the science behind therapeutic monoclonal antibodies, with a focus on specific design elements


Explore the efficacy and safety profile of VYEPTI® (eptinezumab-jjmr) and examine considerations for appropriate patients

Learn about VYEPTI CONNECT, an optional program that offers support throughout the patient journey—from benefits investigations through appeals—as well as information about possible financial assistance that may be available for eligible patients.

This iPub® is sponsored by Lundbeck and is not approved for Continuing Medical Education.

© 2020 Lundbeck. All rights reserved.

VYEPTI and VYEPTI CONNECT are trademarks of Lundbeck Seattle BioPharmaceuticals, Inc.


This website is intended for US healthcare professionals only.